MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Marker Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.20+0.16 (+15.38%)
Close on Oct 19, 2026
- Market cap
- $23.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.18 (+17.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Marker Therapeutics, Inc. saw revenue fall 46.2% to $3.55M over fiscal 2025.
Revenue
$3.55M
-46.2% vs. a year earlier
Operating income
-$10.71M
TTM Q2 2026
EPS, diluted
-$0.46
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $23.18M
- P/E ratio
- –
- Price to sales
- 6.54
- Price to book
- 1.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.55M
- Net income
- -$8.71M
- EPS, diluted
- -$0.46
- Book value per share
- $0.63
- Diluted shares
- 19M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$10.71M
Net income
-$8.71M
EPS, diluted
-$0.46
Free cash flow
–
Reported periodTrailing twelve months